pharma · Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) · IgA Nephropathy (IgAN) · VERA
Vera Therapeutics
VERALOX Therapeutics is a pharma organization headquartered in Frederick, USA. It trades on NYSE under ticker VERA. Primary therapeutic focus areas include Recurrent Low-Grade Serous Ovarian Cancer (LGSOC), IgA Nephropat
4539 Metropolitan Ct, Frederick, Maryland 21704, US HQ
2018 Founded
9 Employees
Public company Type
VERA · NYSE Ticker
Company details
- Status
- Public
- HQ
- 4539 Metropolitan Ct, Frederick, Maryland 21704, US
- Founded
- 2018
- Employees
- 9
- Programs
- 25
- Drugs
- 32
- Patents
- 140
Atacicept Autoinjector Combination, Atacicept
Phase 2 · small molecule · Multiple Autoimmune Glomerular Diseases
Atacicept Autoinjector Combination, Atacicept for Multiple Autoimmune Glomerular Diseases is a Phase 2 program (small_molecule) at Vera Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code VT-001-0060
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Vera Therapeutics
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Multiple Autoimmune Glomerular Diseases
- Status
- active
- Trials
- 1